EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs

Maggie He iD, Joseph Magdy, Maryam Aziz, Jun Tan, Arka Das iD, Stephen B Wheatcroft, Heerajnarain Bulluck iD

Journal of Clinical Medicine · 24.03.2026 · 15 (7) · 2472

DOI: 10.3390/jcm15072472 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.03.2026. Verfasst von Maggie He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Yorkshire Heart Centre, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For nearly two decades, 12 months of dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) has been the standard recommendation. Recent evidence suggests that abbreviated DAPT durations may reduce bleeding without compromising ischemic protection in selected patients. This review synthesizes randomized controlled trials, meta-analyses, and guideline updates published between 2023 and 2025, evaluating abbreviated DAPT strategies after ACS with percutaneous coronary intervention. Immediate aspirin withdrawal after PCI increased early stent thrombosis in NEO-MINDSET and STOPDAPT-3. One-month DAPT followed by ticagrelor monotherapy reduced bleeding without increasing ischemic events in ULTIMATE-DAPT and T-PASS. Three-month strategies demonstrated the most consistent safety profile, with TWILIGHT showing 50% bleeding reduction without increased death, myocardial infarction, or stroke (noting that TWILIGHT included 35% chronic coronary syndrome patients). Clopidogrel monotherapy after abbreviated DAPT increased myocardial infarction in STOPDAPT-2 ACS, highlighting the importance of potent P2Y12 inhibition. Meta-analyses confirmed bleeding reductions with early P2Y12 inhibitor monotherapy across broader populations, though benefits were more pronounced in East Asian cohorts. Abbreviated DAPT strategies offer personalized alternatives to standard 12-month therapy. Three-month DAPT followed by ticagrelor monotherapy represents a reasonable and evidence-supported strategy in selected patients with ACS. Risk stratification tools and individual patient factors should guide therapy duration decisions.

Schlagwörter

Stichwörter der Autor:innen

P2Y12 inhibitorabbreviated DAPTacute coronary syndromebleeding riskdual antiplatelet therapyrisk stratification

Autor:innen und Institutionen

  • Yorkshire Heart Centre, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK.
  • School of Medicine and Dentistry, Griffith University, Gold Coast 4215, Australia.
  • School of Medicine, Worsley Building, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK.
  • Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK.

ORCID-Profile: Maggie He, Arka Das, Heerajnarain Bulluck

Zitieren

APA

He, M., Magdy, J., Aziz, M., Tan, J., Das, A., Wheatcroft, S. B., & Bulluck, H. (2026). Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs. Journal of Clinical Medicine, 15(7), 2472. https://doi.org/10.3390/jcm15072472

Vancouver

He M, Magdy J, Aziz M, Tan J, Das A, Wheatcroft SB, et al. Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs. Journal of Clinical Medicine. 2026;15(7):2472. doi:10.3390/jcm15072472

BibTeX
@article{He2026,
  author = {He, Maggie and Magdy, Joseph and Aziz, Maryam and Tan, Jun and Das, Arka and Wheatcroft, Stephen B and Bulluck, Heerajnarain},
  title = {Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {2472},
  doi = {10.3390/jcm15072472}
}
Kostenlos starten →